Research programme: Ku protein inhibitors - NERx BiosciencesAlternative Names: NHEJ pathway inhibitors - NERx Biosciences
Latest Information Update: 04 Oct 2016
At a glance
- Originator NERx Biosciences
- Class Small molecules
- Mechanism of Action DNA repair inhibitors; DNA-binding protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 27 Sep 2016 Preclinical trials in Cancer in USA before September 2016 (NERx Biosciences pipeline, September 2016)